Minerva Neurosciences (NASDAQ:NERV) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a report issued on Thursday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright cut their price target on shares of Minerva Neurosciences from $11.00 to $7.00 and set a “neutral” rating on the stock in a research report on Thursday, May 2nd.

Minerva Neurosciences Stock Down 0.9 %

Shares of Minerva Neurosciences stock opened at $3.15 on Thursday. Minerva Neurosciences has a twelve month low of $2.26 and a twelve month high of $13.49. The stock has a market cap of $22.02 million, a price-to-earnings ratio of -0.70 and a beta of 0.13. The company’s fifty day moving average is $2.74 and its 200 day moving average is $4.67.

Minerva Neurosciences (NASDAQ:NERV) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($1.13) EPS for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.07. As a group, equities analysts anticipate that Minerva Neurosciences will post -1.89 earnings per share for the current fiscal year.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.